NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Posted by Brenda Bartman on May 12th, 2026

NeuroPace (NASDAQ:NPCE – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06, Zacks reports. The company had revenue of $22.00 million for the quarter, compared to analyst estimates of $21.65 million. NeuroPace had a negative net margin of 21.47% and a negative return on equity of 105.67%.

Here are the key takeaways from NeuroPace’s conference call:

NeuroPace raised full-year 2026 revenue guidance to $99 million-$101 million from $98 million-$100 million, citing stronger visibility in both core RNS demand and modest service revenue. Management said the guide still excludes any contribution from potential IGE expansion.
Q1 revenue for the core business showed 8% year-over-year growth to $22.0 million excluding DIXI, and the company said active prescribers, accounts, and patient pipeline all hit all-time highs. Management pointed to stronger referrals from both Level 4 centers and community channels as key drivers.
The FDA mid-cycle review for the NAUTILUS PMA supplement was described as constructive, and NeuroPace said it remains on track for a mid-year determination. The company has already responded to the agency’s follow-up questions and continues to expect approval on the current timeline.
Clinical evidence remains a major support for the story, with management highlighting 77% median seizure reduction at 18 months in generalized tonic-clonic seizures and an 82% median seizure reduction in the 3-year post-approval focal epilepsy study. They also emphasized favorable safety and meaningful real-world benefits such as fewer injuries and less rescue medication use.
NeuroPace is investing in future growth through commercial hiring, nurse navigators, and new AI-enabled products, including ECoG Assistant and a multimodal foundational model. Management expects ECoG Assistant approval in Q2 2026 and said the product roadmap remains on track, but these initiatives will also raise expenses in the near term.

NeuroPace Stock Performance

Shares of NPCE opened at $15.80 on Wednesday. The company has a current ratio of 5.28, a quick ratio of 4.33 and a debt-to-equity ratio of 3.09. The firm has a market cap of $536.41 million, a PE ratio of -23.94 and a beta of 1.92. NeuroPace has a 12 month low of $7.56 and a 12 month high of $19.60. The stock has a fifty day moving average price of $15.01 and a 200-day moving average price of $15.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its stake in shares of NeuroPace by 23.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,836 shares of the company’s stock worth $230,000 after acquiring an additional 2,778 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in shares of NeuroPace during the third quarter worth $229,000. Man Group plc acquired a new position in shares of NeuroPace in the 3rd quarter valued at about $203,000. BNP Paribas Financial Markets lifted its holdings in NeuroPace by 176.5% in the third quarter. BNP Paribas Financial Markets now owns 18,756 shares of the company’s stock valued at $193,000 after acquiring an additional 11,972 shares during the period. Finally, Engineers Gate Manager LP acquired a new stake in NeuroPace during the fourth quarter valued at $188,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NPCE. Cantor Fitzgerald upgraded NeuroPace to a “strong-buy” rating in a report on Wednesday, March 4th. Wall Street Zen cut NeuroPace from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Wells Fargo & Company raised NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 18th. UBS Group reiterated a “buy” rating on shares of NeuroPace in a research note on Wednesday, January 14th. Finally, HC Wainwright boosted their target price on shares of NeuroPace from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, NeuroPace presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

Check Out Our Latest Analysis on NPCE

About NeuroPace

(Get Free Report)

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.